Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Andrew Goodwin holds a Ph.D. in the cellular and molecular basis of human disease, with research experience in infectious diseases and cancer. After 11 years as an academic scientist I now work on the regulatory side of drug development. Aside from my day job, I operate the websites BiotechDueDiligence and HSP90 Central that provide in-depth, reliable information and education for biotech investors and other readers. I have also contributed to Chimera Research Group, a publisher of subscription-based biopharmaceutical insight. In 2012 I was honored to be named one of the "Top 50 Industry Voices in Biotech" by FierceBiotech and Appeering. Visit my BiotechDueDiligence website for additional bio details.
Apsara Biotech Research provides in-depth research on publicly traded stocks in the biotechnology sector. We pride ourselves on conducting high quality research for our clients and the public markets. Apsara is not affiliated with a broker-dealer and does not underwrite public offerings or provide investment banking services to the companies that it researches. Therefore, the research coverage provided in our reports are not influenced by the prospect of future investment banking and underwriting fee revenue.
Instead, Apsara and its contributors hold long and short positions in the stocks that we write about. Our research commentary is supported by our genuine opinions about the securities covered, rather than a motivation to derive future fee revenue from the subject companies.
We hope that you find our approach to biotechnology sector research refreshing, original and accurate.
Our research director is Yang Yu and can be reached at email@example.com
I am now retired from the US pharma industry having spent over 33 years in the Mid-Atlantic corridor in Sales(Hospital mainly), Scientific Relations and Managed Care/LTC. I worked at BMY, Bayer/Miles Labs and SGP/MRK prior to early retirement..
Today I enjoy investing in Bio-Pharmas mostly, because it is what I know best!
I invest mostly in large companies such as BMY, PFE, MRK, GSK, and JNJ (love the divis) but I like the up and coming Bios like CLDX. Cancer and Immunotherapy intrigues me..so I have made that a major consideration since 2008....With BARDA,the GAIN act and QDIP Ive come to appreciate the Antibiotic cos.and have made them a major component of my LT strategy to build wealth while in Retirement....Ive invested in Trius(TSRX),CBST, CEMP, DRTX, TTPH, CTIX and just added AKAO.....
I manage personal monies and some family members..gratis of course!
I am the Portfolio Manager for the RETIREE INCOME PORTFOLIO, DIVIDEND OVERDRIVE PORTFOLIO, and the OIL & GAS INCOME PORTFOLIO at PortfolioChannel.com. I am also the creator of the Cash Flow Retirement Replacement Ratio© used in retirement and investment planning. A Chartered Financial Analyst and Certified Financial Planner, I have spent over two decades managing high-net worth individual and institutional accounts, working as a portfolio manager and analyst. I have also had several stints working for a pair of Private Banks managing balanced, fixed income, and equity accounts.
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular position. Please click to follow me if you like my work. There’s an option to follow me at the top of my articles. Best functionality of site is on desktop.
OTHER PLACES TO FOLLOW ME:
I’M NOT A FINANCIAL ADVISOR & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;) Investment Philosophy: Understand why you are getting in.
My positions, long or short can change dramatically as new information comes to my attention. All stocks are risky, but, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment.
No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
Daniel Moore is the creator of FinancialRelativity.com, a web portal created for the purpose of tracking the status of financial markets and providing investment analysis and portfolio management insights to investors. Based on the systematic investment research, he writes about the market and publishes his views through internet market publications. He has over 25 years of management experience in corporate finance in a variety of high technology start-ups and public companies. A graduate of Duke University’s Fuqua School of Business in 1988, he has spent the last 10 years managing investment portfolios seeking high risk reward returns for fixed income investors.
Mark Bern (formerly K202) intends to continue writing solo and has shed other work-related relationships that required anonymity.
CPA since 1990 a CFA charter holder since 2000. He has a bachelors degree in Business Admin. with a concentration in Economics. His experience includes both private and public sector and careers in accounting, financial and market analysis, product development, transportation services and investment management.
Elliott Gue knows energy. Since earning his bachelor’s and master’s degrees from the University of London, Elliott has dedicated himself to learning the ins and outs of this dynamic sector, scouring trade magazines, attending industry conferences, touring facilities and meeting with management teams.
For seven years, Elliott Gue shared his expertise and stock-picking abilities with individual investors through a highly regarded, energy-focused research publication. Elliott Gue’s knowledge of the sector and prescient investment calls prompted the official program of the 2008 G-8 Summit in Tokyo to call him “the world’s leading energy strategist.”
He has also appeared on CNBC and Bloomberg TV and has been quoted in a number of major publications, including Barron’s, Forbes and the Washington Post.
In October 2012, Elliott Gue launched the Energy & Income Advisor (www.EnergyandIncomeAdvisor.com), a semimonthly online newsletter that’s dedicated to uncovering the most profitable opportunities in the energy sector, from growth stocks to high-yielding utilities, royalty trusts and master limited partnerships.
The masthead may have changed, but subscribers can expect the same in-depth analysis and rational assessments of investment opportunities in the energy sector.
I have been a VP and Treasurer for a Fortune 500 Company and CFO for 3 other firms including a bank holding company, a mini-conglomerate and a consumer finance company. I have an MS in Finance, with a specialization in Investments, and am a CPA.